Medicine
Trulance Immediate release 3 mg tablet
Trulance Immediate release 3 mg tablet is a prescription medicine containing Plecanatide for oral use, marketed by Salix Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at room temperature, 20 to 25°C (68 to 77°F), excursions permitted to 15…
Key facts
- Active ingredient (INN)
- Plecanatide
- Brand
- Trulance Immediate release
- Strength
- 3 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 bottle, 30 tablets
- Marketing authorisation holder
- Salix Pharmaceuticals
- Manufacturer
- Salix Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at room temperature, 20 to 25°C (68 to 77°F), excursions permitted to 15 to 30°C (59 to 86°F). Protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A06AX07 Plecanatide
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 February 2017
- Identifiers
- RxCUI 1873757, 1873765DailyMed set ID fe2895bf-71a6-493a-b0ca-e06b2dfefc82NDC 65649-003Application NDA208745
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 1 tablet in 1 bottle | 65649-003-01 | Salix Pharmaceuticals | 21 February 2017 |
| 1 bottle in 1 carton / 3 tablet in 1 bottle | 65649-003-03 | Salix Pharmaceuticals | 21 February 2017 |
| 30 tablet in 1 bottle | 65649-003-30 | Salix Pharmaceuticals | 21 February 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 19 January 2017 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Plecanatide is a guanylate cyclase-C agonist indicated in adults for the treatment of chronic idiopathic constipation (CIC). It is available as tablets for oral use. MedsAcross supplies Plecanatide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PlecanatideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Trulance Immediate release prescribing information (Salix Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Trulance Immediate release 3 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.